期刊
VIRUSES-BASEL
卷 12, 期 11, 页码 -出版社
MDPI
DOI: 10.3390/v12111214
关键词
COVID-19; SARS-COV-2; convalescent plasma; ELISA; neutralization; virus capture assay
类别
资金
- Ministere de l'Economie et de l'Innovation du Quebec, Programme de soutien aux organismes de recherche et d'innovation
- Fondation du CHUM
- Canadian Institutes of Health Research, via the Immunity Task Force
- Canada Research Chair on Retroviral Entry [RCHS0235 950-232424]
- MITACS Acceleration postdoctoral fellowship
- CIHR graduate fellowship
Convalescent plasma from SARS-CoV-2 infected individuals and monoclonal antibodies were shown to potently neutralize viral and pseudoviral particles carrying the S glycoprotein. However, a non-negligent proportion of plasma samples from infected individuals, as well as S-specific monoclonal antibodies, were reported to be non-neutralizing despite efficient interaction with the S glycoprotein in different biochemical assays using soluble recombinant forms of S or when expressed at the cell surface. How neutralization relates to the binding of S glycoprotein in the context of viral particles remains to be established. Here, we developed a pseudovirus capture assay (VCA) to measure the capacity of plasma samples or antibodies immobilized on ELISA plates to bind to membrane-bound S glycoproteins from SARS-CoV-2 expressed at the surface of lentiviral particles. By performing VCA, ELISA, and neutralization assays, we observed a strong correlation between these parameters. However, while we found that plasma samples unable to capture viral particles did not neutralize, capture did not guarantee neutralization, indicating that the capacity of antibodies to bind to the S glycoprotein at the surface of pseudoviral particles is required but not sufficient to mediate neutralization. Altogether, our results highlight the importance of better understanding the inactivation of S by plasma and neutralizing antibodies.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据